CPI-613 and Hydroxychloroquine for Patients With High Risk Myelodysplastic Syndrome

NCT03929211 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

WITHDRAWN

Status

OTHER

Sponsor class

Stopped Administrative withdrawal by IRB

Conditions

Myelodysplastic Syndromes
Progressive Disease

Interventions

DRUG: CPI-613
DRUG: Hydroxychloroquine

Sponsor

Wake Forest University Health Sciences

Collaborators

[object Object]